Las Vegas, NV -- (SBWIRE) -- 12/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Oncomed Pharmaceuticals Inc (NASDAQ:OMED), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), CytRx Corporation (NASDAQ:CYTR)
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) managed to keep its gain at 7.04% on above-normal volume of 2.86M shares. The stock settled at $29.65 after floating in a range of $27.70 to $32.39. Its latest price has reached market capitalization of $825.16 million. Its 52-week range has been $12.06 to $32.39. OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs.
For How Long OMED will fight for Profitability? Read This Trend Analysis report
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) traded up on a volume of 2.82 million, higher than its standard daily volume. Shares have gained 2.27% to $2.70. Over the last twelve months, the stock has lost-67.47% and faced a worst price of $2.40. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.
For How Long RIGL’s Gloss will Attract Investors? Find out via this report
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) settled 10.24% higher at $1.83 on above-normal volume of 2.72M shares during the last trading day. The stock has its 12-month high at $3.59 and 52-week low price was $1.11. It traded in a range of $1.65 to $1.84 during the last trading day. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents.
Why Should Investors Buy NAVB After the Recent Fall? Just Go Here and Find Out
In the last trading session, CytRx Corporation (NASDAQ:CYTR) was up on high volume, trading at a volume of 2.42M versus its average daily volume of 509,746.00 shares. At $2.49, the stock has attained market capitalization of 104.52 million. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.
Will CYTR Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)